Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression Treatment ...

Innovative Study Design Focused on Early Proof-of-Concept Data The Phase I/IIa trial ... protocol is designed to deliver early, robust proof-of-concept data, advancing Ketamir-2's clinical ...

Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical ... for the trial is set to begin in Q1 2025, with initial safety and efficacy results from the Phase I study in ...

In this ongoing open-label, multicenter, dose-escalation Phase ... a Clinical Trial Collaboration Agreement with Merck (known as MSD outside of the US and Canada), for a Pyxis Oncology-sponsored study ...

The BEXMAB study is an open-label Phase 1/2 clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive haematological malignancies of acute myeloid ...

MSD and Moderna have kicked off another phase 3 trial ... MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non-small cell lung cancer (NSCLC). The new study ...

We look forward to enrolling patients and anticipate sharing preliminary clinical data from the trial in the first half of 2025.” Overall, the multicenter, open-label, phase 1/2 ... the protocol ...

--(BUSINESS WIRE)--Uvax Bio, LLC, (“Uvax” or “the Company”) a privately held, clinical ... our first Phase 1 trial is progressing smoothly, and we have preliminary confirmation that UVAX-1107 was well ...

this would occur if the client requested protocol version 4.0, which does not exist as of this writing). If the minor version requested by the client is not supported by the server (e.g., the client ...